Impact of IFNL4 genotype on interferon-stimulated gene expression during daa therapy for Hepatitis C

Journal article

New directly acting antivirals (DAAs) provide very high cure rates in most patients infected by hepatitis C virus (HCV). However, some patient groups have been relatively harder to treat including those with cirrhosis or infected with HCV genotype 3. In the recent BOSON trial, genotype 3, cirrhotic patients receiving a 16 week course of sofosbuvir and ribavirin had a sustained virologic response rate (SVR) of around 50%. In cirrhotic patients, IFNL4 CC genotype was significantly associated with SVR. This genotype was also associated with a lower interferon‐stimulated gene (ISG) signature in peripheral blood and in liver at baseline. Unexpectedly, patients with the CC genotype showed a dynamic increase in ISG expression between weeks 4 and 16 of DAA therapy, while the reverse was true for non‐CC patients. These data provide an important dynamic link between host genotype and phenotype in HCV therapy also potentially relevant to naturally acquired infection.

Authors: Ramamurthy, N; Marchi, E; Ansari, M; Pedergnana, V; MClean, A

• Publication status: Published
• Peer review status: Peer reviewed
• Publisher: Wiley
• Journal: Hepatology
• Volume: 68
• Issue: 3
• Pages: 859-871
• Publication date: 2018-09-15
• Acceptance date: 2018-03-08
• DOI: 10.1002/hep.29877
• EISSN: 1527-3350
• ISSN: 0270-9139